Filing Flows › Health Care › Evofem Biosciences (EVFM)
Evofem Biosciences (EVFM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Evofem Biosciences (EVFM) Q2 2026 earnings results →
Q2 2026 Revenue down 45% year over year to $2.6M · 419¢ of every $1 of revenue lost · operating margin -94.5%
Evofem Biosciences made $2.6M in Q2 2026 (-45% Y/Y). Operating margin -94.5%, net loss $11.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.6M in Q2 2026, down 45% year over year and up 193% from the previous quarter.
Operating costs exceeded revenue by $2.5M, an operating margin of -94.5%. Total costs fell 16% while revenue fell 45%. The quarter ended with a net loss of $11.0M, wider than the previous quarter's $5.5M loss. Net interest and other expense of $8.5M was the main reason.
Operating cash flow was −$3.1M. Non-cash charges added back $18K of depreciation and amortization. Working capital and other items added $7.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $2.6M | -45% | -94.5% | −$11.0M | −$3.1M |
| Q1 2026 | 10-Q | May 15, 2026 | $899K | +6% | -508.2% | −$5.5M | $2.3M |
| Q4 2025 | 10-K | Mar 11, 2026 | $9.6M | +35% | 35.0% | $2.8M | $31K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $5.0M | +10% | 19.2% | −$1.6M | $336K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $4.8M | +16% | -25.9% | −$1.8M | −$2.9M |
| Q1 2025 | 10-Q | May 15, 2025 | $845K | -76% | 38.7% | $956K | $560K |
| Q4 2024 | 10-K | Mar 24, 2025 | $7.1M | +47% | -14.1% | −$3.0M | −$2.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Evofem Biosciences
We are a San Diego-based commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Our first commercial product, PHEXX ® , was approved by the FDA on May 22, 2020, for the prevention of pregnancy and launched in the U.S. in September 2020. PHEXX is the first and only non-hormonal prescription contraceptive vaginal gel. Women use it when they have sex, inserting PHEXX 0-60 minutes prior to intercourse. Because PHEXX is hormone-free and non-systemic, it is not associated with side effects of hormonal contraceptive methods, which include depression, weight gain, headaches, loss of libido, mood swings and irritability.
In its own words, from its 10-K, filed Mar 11, 2026.
Evofem Biosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -45% against the peers' median +7%. Operating margin: -94.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EVFM Evofem Biosciences | Q2 2026 | $2.6M | -45% | -94.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Evofem Biosciences 10-Q on SEC EDGAR · CIK 1618835 · Pharmaceutical Preparations
More on EVFM
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results